Eduarda Chiesa Ghisleni

Eduarda Chiesa Ghisleni

Auto-generated profile, based on publicly available information

Eduarda Chiesa Ghisleni

Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Post-Graduate Program in Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
LGLivia A Goldraich
Livia A Goldraich
JNJeruza L Neyeloff
Jeruza L Neyeloff
Ana Paula Beck da Silva EtgesAna Paula Beck da Silva Etges
Ana Paula Beck da Silva Etges
LZLais G Zeilmann
Lais G Zeilmann
LHLaura T Hastenteufel
Laura T Hastenteufel
NCNadine Clausell
Nadine Clausell

29 October 2023 in Clinics
Verified
Journal Article
Open access
EGEduarda Chiesa Ghisleni
Eduarda Chiesa Ghisleni
VAVitória Rech Astolfi
Vitória Rech Astolfi
LZLarissa Zimmermann
Larissa Zimmermann
CLCamila Nogueira Leandro Lira
Camila Nogueira Leandro Lira
ENEduarda Faria Do Nascimento
Eduarda Faria Do Nascimento
ABAndreia Biolo
Andreia Biolo
To measure Quality of Life (QoL) and costs of Heart Failure (HF) outpatients in Brazil as an introduction to the Value-Based Health Care (VBHC) concept. Cross-sectional study, patients with HF, with ejection fraction <50%, were recruited from three hospitals in Brazil. Two QoL (36-Item Short Form Survey [SF-36] and Minnesota Living with Heart Failure Questionnaire [MLHFQ]) and two anxiety/depression questionnaires were applied. SF-36 scores were stratified by domains. Treatment costs were calculated using the Time-Driven Activity-Based Costing (TDABC) method. Results were stratified by NYHA functional class and sex. From October 2018 to January 2021, 198 patients were recruited, and the median MLHFQ (49.5 [IQR 21.0, 69.0]) and SF-36 scores demonstrated poor QoL, worse at higher NYHA classes. A third of patients had moderate/severe depression and anxiety symptoms, and women had higher anxiety scores. Mean costs of outpatient follow-up were US$ 215 ± 238 for NYHA I patients, US$ 296 ± 399 for NYHA II and US$ 667 ± 1012 for NYHA III/IV. Lab/exam costs represented 30% of the costs in NYHA I, and 74% in NYHA III/IV (US$ 63.26 vs. US$ 491.05). Patients with HF in Brazil have poor QoL and high treatment costs; both worsen as the NYHA classification increases. It seems that HF has a greater impact on the mental health of women. Costs increase mostly related to lab/exams. Accurate and crossed information about QoL and costs is essential to drive care and reimbursement strategies based on value.